Stahl Andreas, Hellstrom Ann, Smith Lois E H
Eye Center, University of Freiburg, Freiburg, Germany.
Neonatology. 2014;106(3):254-60. doi: 10.1159/000365132. Epub 2014 Oct 5.
Treatment of retinopathy of prematurity (ROP) is currently evolving. Novel therapeutic options are emerging that have the potential to complement existing therapies and improve treatment outcomes. However, any new therapeutic option must be thoroughly evaluated before existing (and successful) treatment paradigms can be amended. This is particularly so when switching from locally effective therapies like photoablative laser therapy to systemic pharmacological treatments, which may have hitherto unknown widespread side effects. This review compiles the current knowledge of where and when the two most advanced pharmacological treatment options for ROP, insulin-like growth factor-1 supplementation and anti-vascular endothelial growth factor treatment, may have their place in future therapy regimens for ROP. The requirement for clinical studies is emphasized: these are needed to address safety considerations before any of these interventions can achieve the status of standard clinical care in the very vulnerable population of ROP infants.
早产儿视网膜病变（ROP）的治疗目前正在不断发展。新的治疗选择不断涌现，有可能补充现有疗法并改善治疗效果。然而，在修改现有的（且成功的）治疗模式之前，任何新的治疗选择都必须经过全面评估。从光凝激光治疗等局部有效疗法转向全身药物治疗时尤其如此，因为全身药物治疗可能会有迄今未知的广泛副作用。本综述汇集了关于ROP的两种最先进药物治疗选择（补充胰岛素样生长因子-1和抗血管内皮生长因子治疗）在未来ROP治疗方案中可能适用的时机和情况的当前知识。强调了临床研究的必要性：在这些干预措施中的任何一项能够在ROP婴儿这一非常脆弱的人群中达到标准临床护理的地位之前，都需要进行临床研究以解决安全性问题。
